Patent Grant
9333302
The present application is a U.S. National Phase Application pursuant to 35 U.S.C. §371 of International Application No. PCT/EP2011/071143 filed Nov. 28, 2011, which claims priority to European Patent Application No. 10192846.3 filed Nov. 29, 2010. The entire disclosure contents of these applications are herewith incorporated by reference into the present application.
This present patent application relates to drug delivery devices and methods of delivering at least two drug agents from separate reservoirs using devices having only a single dispense interface. The drug agents are contained in two or more multiple dose reservoirs, containers or packages, each containing independent (single drug compound) or pre-mixed (co-formulated multiple drug compounds) drug agents. The disclosed method and system is of particular benefit where the therapeutic response can be optimized for a specific target patient group, through control and definition of the therapeutic profile. More particularly, the disclosed method and system is of particular benefit where one of the two drug agents is administered by way of at least one discrete pulse of medicament.
Certain disease states require treatment using one or more different medicaments. Some drug compounds need to be delivered in a specific relationship with each other in order to deliver the optimum therapeutic dose. The disclosed method and system is of particular benefit where combination therapy is desirable, but not possible in a single formulation for reasons such as, but not limited to, stability, compromised therapeutic performance and toxicology.
For example, in some cases it might be beneficial to treat a diabetic with a long acting insulin and with a glucagon-like peptide-1 (GLP-1), which is derived from the transcription product of the proglucagon gene. GLP-1 is found in the body and is secreted by the intestinal L cell as a gut hormone. GLP-1 possesses several physiological properties that make it (and its analogs) a subject of intensive investigation as a potential treatment of diabetes mellitus.
There are a number of potential problems when delivering two active medicaments or “agents” simultaneously. The two active agents may interact with each other during the long-term, shelf life storage of the formulation. Therefore, it is advantageous to store the active components separately and only combine them at the point of delivery, e.g. injection, needle-less injection, pumps, or inhalation. However, the process for combining the two agents needs to be simple and convenient for the user to perform reliably, repeatedly and safely.
A further problem is that the quantities and/or proportions of each active agent making up the combination therapy may need to be varied for each user or at different stages of their therapy. For example, one or more actives may require a titration period to gradually introduce a patient to a “maintenance” dose. A further example would be if one active requires a non-adjustable fixed dose while the other is varied in response to a patient's symptoms or physical condition. This problem means that pre-mixed formulations of multiple active agents may not be suitable as these pre-mixed formulations would have a fixed ratio of the active components, which could not be varied by the healthcare professional or user.
Additional problems may arise where a multi-drug compound therapy is required, because certain users cannot cope with having to use more than one drug delivery system or make the necessary accurate calculation of the required dose combination. This is especially true for users with dexterity or computational difficulties.
Accordingly, there exists a strong need to provide devices and methods for the delivery of two or more medicaments in a single injection or delivery step that is simple for the user to perform. The disclosed method and system overcomes the above-mentioned problems by providing separate storage containers for two or more active drug agents that are then only combined and/or delivered to the patient during a single delivery procedure. Setting a dose of one medicament automatically fixes or determines the dose of the second medicament (i.e. non-user settable).
The disclosed method and system also gives the opportunity for varying the quantity of one or both medicaments. For example, one fluid quantity can be varied by changing the properties of the injection device (e.g. dialing a user variable dose or changing the device's “fixed” dose). The second fluid quantity can be changed by manufacturing a variety of secondary drug containing packages with each variant containing a different volume and/or concentration of the second active agent. The user or healthcare professional would then select the most appropriate secondary package or series or combination of series of different packages for a particular treatment regime. Alternatively, the second fluid quantity can be changed by varying the properties of the fixed dose mechanism, such as a linkage component dispose on a fixed dose setting mechanism. The disclosed system and method may achieve a wide variety of target therapeutic profiles. For example, the disclosed system and method may achieve a therapeutic dose profile that delivers a fixed dose of a secondary medicament once a minimum setting threshold dose of a primary medicament has been set. As another example, the disclosed system and method may achieve a stepped fixed dose profile. As another example, the disclosed system and method may provide for the continuous administration of a variable dose of a first or primary medicament in combination with a pulsed or incremental administration of a fixed dose. Specifically, the disclosed system and method, in one arrangement, provides a means of selecting and delivering a combination dose of a user selectable dose of a first medicament with a non-user settable dose of a second medicament, wherein the delivery of the second medicament is ‘pulsed’ during delivery (e.g., sequential delivery) of the first medicament.
These and other advantages will become evident from the following more detailed description of the invention.
The disclosed system and method allows complex combination of multiple drug compounds within a single device. In particular, the disclosed system and method allows the user to set and dispense a multi-drug compound device through a single dose setter and a single dispense interface. The drug delivery system includes a variable dose setting mechanism and a fixed dose setting mechanism. The system also includes a collar disposed on the variable dose setting mechanism and a linkage component disposed on the fixed dose setting mechanism, where the linkage component is capable of engagement with the collar. In an example, the single dose setter controls the dose setting mechanisms of the device such that a predefined combination of the individual drug compounds is delivered when a single minimum dose of one of the medicaments is set and dispensed through the single dispense interface.
By defining the therapeutic relationship between the individual drug compounds, Applicants' delivery device would help ensure that a patient/user receives the optimum therapeutic combination dose from a multi-drug compound device without the inherent risks associated with multiple inputs, where the user has to calculate and set the correct dose combination every time they use the device. The medicaments can be fluids, defined herein as liquids, gases or powders that are capable of flowing and that change shape at a steady rate when acted upon by a force tending to change its shape. Alternatively, one of the medicaments may be a solid that is carried, solubilized or otherwise dispensed with another fluid medicament.
This disclosed system is of particular benefit to users with dexterity or computational difficulties as the first variable input and second controlled/limited input (and the associated controlled therapeutic profile) removes the need for them to calculate their prescribed dose every time they use the device and this arrangement allows considerably easier setting and dispensing of the combined compounds.
In an embodiment of the proposed system, a master drug compound, such as insulin, is contained within a primary reservoir and a secondary medicament is contained within a secondary reservoir. Although Applicants' present patent application specifically mentions insulin, insulin analogs or insulin derivatives, and GLP-1 or GLP-1 analogs as two possible drug combinations, other drugs or drug combinations, such as an analgesics, hormones, beta agonists or corticosteroids, or a combination of any of the above-mentioned drugs could be used with Applicants' proposed system and method.
For the purposes of Applicants' system and method the term “insulin” shall mean Insulin, insulin analogs, insulin derivatives or mixtures thereof, including human insulin or a human insulin analogs or derivatives. Examples of insulin analogs are, without limitation, Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin or Des(B30) human insulin. Examples of insulin derivatives are, without limitation, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyhepta-decanoyl) human insulin.
As used herein the term “GLP-1” shall mean GLP-1, GLP-1 analogs, or mixtures thereof, including without limitation, exenatide (Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys- Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2), Exendin-3, Liraglutide, or AVE0010 (H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2).
Examples of beta agonists are, without limitation, salbutamol, levosalbutamol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, salmeterol, formoterol, bambuterol, clenbuterol, indacaterol.
Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
One embodiment of Applicants' disclosure relates to a drug delivery system to deliver two or more medicaments through a single dispense interface, where the device has a housing containing a first user-operable dose setter operably connected to a primary reservoir of a first medicament containing multiple doses of at least one drug agent. The device also contains a second dose setting mechanism operably connected to a second reservoir of a second medicament containing multiple doses of at least one drug agent. A dose button is operably connected to the primary reservoir of medicament and a single dispense interface is configured for fluid communication with the primary reservoir. The secondary reservoir of a second medicament containing multiple fixed doses of at least one drug agent is configured for fluid communication to the single dispense interface.
This dose button can be any type of mechanism that triggers the delivery procedure, whether driven mechanically or through a combination of electronics and mechanics. The button can move or be a touch sensitive virtual button, for example, a touch sensitive screen. Applicants' system has a single dispense interface configured for fluid communication with the primary reservoir and with a secondary reservoir of medicament containing at least one drug agent. The drug dispense interface can be any type of outlet that allows the two or more medicaments to exit the system and be delivered to the patient. Types of interfaces include hollow needles, catheters, atomizers, pneumatic injectors, or needle-less injectors, mouthpieces, nasal-applicators and the like interfaces.
Preferably, the secondary reservoir preferably contains multiple fixed doses of medicament but alternatively could also contain a single fixed dose of medicament. As mentioned above, the system is designed such that a single activation of the dose button causes the user set dose of medicament from the primary reservoir and a non-user set dose of medicament from the second reservoir to be expelled through the single dispense interface. By user settable dose it is meant dose that the user (patient or health care provider) can physically manipulate the device to set a desired dose. Additionally, the user settable dose can be set remotely through the use of wireless communication (Bluetooth, WiFi, satellite, etc.) or the dose could be set by another integrated device, such as a blood glucose monitor after performing a therapeutic treatment algorithm. By non-user set dose it is meant that the user (or any other input) cannot independently set or select a dose of medicament from the secondary reservoir. In other words, when the user (or another input as described above) sets the dose of the primary medicament in the primary reservoir, the fixed dose of the second medicament is automatically set. However, in some examples, it may be possible for a user to adjust the device prior to setting a dose in order to alter the threshold dose where the fixed dose will be set.
In an example of Applicants' proposed system, a drug delivery device includes a variable dose setting mechanism, a fixed dose setting mechanism, a single dose setter, a collar, and a linkage component. The variable dose setting mechanism is operably coupled to a primary reservoir holding a first medicament. The fixed dose setting mechanism comprises a fixed dose piston rod that is operably coupled to a secondary reservoir holding a second medicament. Further, the single dose setter is operably coupled to the variable dose setting mechanism. Still further, the collar is disposed on the variable dose setting mechanism, and the linkage component is disposed on the fixed dose setting mechanism. The linkage component is capable of engagement with the collar.
In an example, the collar is a ring-shaped collar having a gap between a first end of the collar and the second end of the collar, wherein the collar comprises a groove, and wherein the linkage component comprises a pin that is slidably engageable with the groove. In another example, the collar comprises a groove having a plurality of sections, wherein a first section is a generally flat section and a second section is a helical section, and wherein the linkage component comprises a pin that is slidably engageable with the groove. In yet another example, the collar comprises a first section having a first groove projection and a second section having a second groove projection, wherein the linkage component is capable of engagement with the first groove projection after a first minimum dose of the first medicament is set, and wherein the linkage component is capable of engagement with the second groove projection after a second minimum dose higher than the first minimum dose is set.
Applicants' present disclosure also covers a method of dispensing a fixed dose of one medicament and a variable dose of another medicament from separate reservoirs that involves the steps of first setting a dose of a first medicament contained in a primary reservoir of a drug delivery device having a single dose setter. This setting of the first dose automatically sets the dose from a secondary reservoir (e.g., after a minimum first dose threshold is exceeded) without a separate input by the user. Next a dose button is activated that moves both the set dose of the first medicament from the primary reservoir and the automatically set non-user settable dose from the secondary reservoir through a single dispense interface. Preferably, the non-user settable dose from the secondary reservoir is administered by way of at least one discrete pulse during the administration process.
The combination of compounds as discrete units or as a mixed unit can be delivered to the body via an integral needle. This would provide a combination drug injection system that, from a user's perspective, would be achieved in a manner that very closely matches the currently available injection devices that use standard needles. One possible delivery procedure would involve the following steps:
Delivery of the second medicament in discrete pulses has certain advantages. For example, pulsed delivery may be preferable for situations where the two compounds need to be delivered together, but where the pharmacokinetics of the therapy might be improved if the mixing of the two compounds ‘in vivo’ is actively promoted/assisted (i.e. having a single ‘slug’ or discrete pulse of the secondary medicament delivered alongside the dose of the primary medicament, either at the start or end of the delivery stroke, is less desirable than splitting the dose of the secondary medicament into a series of small parts and delivering them at spaced intervals during the dispense stroke). For example, this may be caused if the 2 compounds are generally not miscible.
A particular benefit of Applicants' proposed system and method is that the use of two multi-dose reservoirs makes it is possible to tailor dose regimes when required, especially where a titration period is necessary for a particular drug. In an example, a set of drug delivery devices may be provided that have second dose setting mechanisms and/or reservoirs that have different properties, and thus result in different fixed doses of a second medicament. The drug delivery devices could be supplied in a number of titration levels with obvious differentiation features such as, but not limited to, aesthetic design of features or graphics, numbering etc, so that a user could be instructed to use the supplied drug delivery devices in a specific order to facilitate titration. Alternatively, the prescribing physician may provide the patient with a number of “level one” titration drug delivery devices and then when these were finished, the physician could then prescribe the next level.
A further feature of an example of Applicants' proposed system and method is that both medicaments are delivered via one injection needle and in one injection step. This offers a convenient benefit to the user in terms of reduced user steps compared to administering two separate injections. This convenience benefit may also result in improved compliance with the prescribed therapy, particularly for users who find injections unpleasant, or who have dexterity or computational difficulties. The use of one injection instead of two reduces the possibility for user errors and so may increase patient safety.
These as well as other advantages of various aspects of the present invention will become apparent to those of ordinary skill in the art by reading the following detailed description, with appropriate reference to the accompanying drawings.
Exemplary embodiments are described herein with reference to the drawings, in which:
The drug delivery system of the present disclosure administers a combined dose that includes a variable dose of a first medicament (primary drug compound) and a fixed dose of a second medicament (secondary drug compound). This combined dose is delivered by continuously delivering the first medicament throughout the dose administration procedure while delivery of the second medicament occurs by way of one or more discrete pulses during this same procedure. Administration takes place through a single output or drug dispense interface. Setting the dose of the primary medicament by the user can set a first fixed dose of the second medicament once a minimum or first threshold dose of the primary medicament is achieved. If the user sets a dose equal to a second threshold dose of the primary medicament (i.e., one greater than the first threshold dose), a second fixed dose of the second medicament may be achieved. In an example, the drug dispense interface is a needle cannula (hollow needle).
Returning to
The cartridges may be housed in cartridge holders 5 and 6 that have attachment means compatible with a removable, disposable hub or housing 4 that contains the single dispense interface. In this example the single dispense interface is shown as output needle 3. The hub can be of any design, provided that it allows for fluid communication between the primary and secondary medicaments and the single dispense interface or needle 3. An example design of hub 4 would include what is generally referred to in the art as a “2-to-1 needle” configuration. Although not shown, hub 4 could be supplied by a manufacturer contained in a protective and sterile capsule or container where the user would peel or tear open a seal or the container itself to gain access to the sterile single dispense interface. In some instances it might be desirable to provide two or more seals for each end of the hub. The seal may allow display of information required by regulatory labeling requirements. When a needle is used to deliver the medicaments it is preferred that the hub is designed to be economical and safe for allowing the user to attach a new hub for each injection. Attachment of hub 4 to the multi-use device 10 creates a fluid connection between output needle 3 and medicaments 1 and 2.
The example in
As generally understood by those skilled in the art, it may be convenient to use lead screws or spindles to push on or drive a piston or bung contained within a cartridge of medicament. As such, spindles may be used in each dose delivery assembly. By varying the spindle pitches it is possible to vary the dose sizes (and dose ratio) in relation to each other. Specifically, this allows variation of the therapeutic profile to suit a specific therapy or patient requirements by providing devices with different dose ratios. The device shown in
Varying the spindle pitches of the individual device mechanisms in relation to each other may alter the relationship of the fixed ratio of medicaments. Variation of the spindle pitch changes the advance of the spindle during dispense for a given amount of rotation during setting. Differing amounts of advance between the two mechanisms has the effect of creating different dispense ratios between the mechanisms. Variation of the spindle pitches may have the effect of extending the operational window of delivery device 10 in terms of the range of fixed ratios that can be achieved. This may also assist in keeping the spindle pitch in a range that allows resetting should the device be required to be reusable. This means that multiple pen injectors each having a different therapeutic profile can be manufactured. Specifically, this allows variation of the therapeutic profile to suit a specific titration regime and ultimately individual patient requirements.
The attachment means between hub 4 and cartridge holders 5 and 6 can be those known to those skilled in the art, including threads, snap locks, snap fits, luer locks, bayonet, snap rings, keyed slots, and combinations of such connections. The connection or attachment between the hub and the cartridge holder may also contain additional features (not shown), such as connectors, stops, splines, ribs, grooves, pips, clips and the like design features, that ensure that specific hubs are attachable only to matching drug delivery devices.
The shape of the dispense device 10, including hub 4, may be generally oval and/or cylindrical or any other geometric shape suitable for hand manipulation by a user. Additionally, hub 4 could incorporate a safety shield device that would prevent accidental needle sticks and reduce the anxiety experienced by users who suffer from needle phobia. The exact design of the safety shield is not critical to the drug delivery device, however, an example design is one that is operably connected to the first and/or second reservoirs. In such a design the activation of the safety shield could unlock the drug delivery system or instigate fluid communication between the reservoirs and in some cases cause the second medicament to be dispensed prior to activating the dose button to dispense the primary medicament from the first reservoir. Another example design would physically prevent insertion of the used drug dispense interface into the patient (e.g. a single use needle-guard type arrangement).
As mentioned an example design of Applicants' drug delivery device would include cartridges to contain the medicaments. Cartridges are typically cylindrical in shape and are usually manufactured in glass, sealed at one end with a rubber bung (piston) and at the other end by a rubber septum using a metal ferrule. The dose delivery assemblies are typically powered by a manual action of the user. However, the injection mechanism may also be powered by other means such as a spring, compressed gas or electrical energy.
A drug delivery device in accordance with Applicants' proposed concept may include a collar and a linkage component that mechanically link a variable dose setting mechanism and a fixed dose setting mechanism.
The drug delivery device 100 also includes a single dose setter 106 that is operably coupled to the variable dose setting mechanism 102. A collar 108 is disposed on the variable dose setting mechanism 102 and a linkage component 110 is disposed on the fixed dose setting mechanism 104. In the example depicted, the linkage component is a pin. However, other types of components are possible, including but not limited to a flange element. The collar and pin arrangement between the dose setting mechanism 102, 104 may result in a desired dose profile, such as a profile that comprises a variable dose of the first medicament 1 and a delayed, fixed dose of the second medicament 2, such as that shown in
The collar 108 may be disposed on the variable dose setting mechanism 102 at various locations. For example, in the example of
The setting and dispensing phases are depicted in detail in
When the pin is lifted to the set point of the fixed dose setting mechanism 104, the gap 116 in the collar 108 allows the pin to disengage from the groove 122. The set point of fixed dose setting mechanism 104 is shown in
Drug delivery device 100 may beneficially deliver a therapeutic dose profile that involves delivering a variable dose of a first medicament and delivering a fixed dose of a second medicament after a minimum dose of the first medicament is set. An example of such a profile is shown in
For low dose settings of the first medicament 1 below the minimum threshold 152, the fixed dose setting mechanism does not reach its set point. In some examples, if this is the case, none of the second medicament would be dispensed. That is, the fixed dose setting mechanism 104 may be configured to only dispense medicament after a full fixed dose is set. Should a dose less than the full dose be set, the fixed dose setting mechanism may simply be configured to return to its starting position without dispensing a dose. Thus, the drug delivery device 100 beneficially may allow for priming of the device using just the first medicament 1. The device 100 may be particularly advantageous for examples where the second medicament 2 is particularly expensive compared to the first medicament 1. Since the fixed dose of the second medicament may not be set until a minimum dose of the first medicament 1 is set, the user may dial a priming dose (e.g., a dose less than dose 152) and prime solely with the first medicament.
A second example drug delivery device is shown in
These various components are generally the same as or similar to the corresponding components of drug delivery device 100; however, drug delivery device 200 has a modified collar 208 and a modified fixed dose setting mechanism 204. This modified collar 208 allows for achieving a modified therapeutic dose profile. Further, the modified fixed dose setting mechanism 204 allows for setting of a fixed dose that follows a stepped fixed dose profile. In other words, the fixed dose setting mechanism allows for the settable fixed dose to increase in increments based on the value of the dialed variable dose. Similar to the fixed dose mechanism 104, fixed dose setting mechanism 204 may be an axially-set fixed dose setting mechanism. As is generally known in the art, such devices may contain ratchet features to facilitate setting of a dose of medicament. In this case, additional ratchet features may be required to allow for half dose setting as well as full dose setting (described below). In a particular example, approximately 28 ratchet steps would be used; however, this number of ratchet steps can vary as needed. For example, having ratchet steps in multiples of 7 may be potentially beneficial as it relates directly to weeks, making planning for replacement prescriptions etc easier for a user. In one exemplary arrangement, Applicants' device may be configured such that the device has an additional, setting that facilitates priming. After this prime dose, the device is capable of delivering 14 further, ‘complete’ doses.
Specifically, the modified collar includes a groove having a plurality of sections. For example, the collar may comprise a groove having at least a first section that is a generally flat section and a second section that comprises a helical section. For instance, the collar 208 depicted in
A collar such as collar 208 may beneficially achieve a stepped fixed dose profile. In particular, drug delivery device 200 may beneficially deliver a therapeutic dose profile that involves delivering a variable dose of a first medicament and delivering a stepped, fixed dose of a second medicament. For instance, a first fixed dose amount of the second medicament 2 may be set after a first minimum dose of the first medicament 1 is set, and a second fixed dose amount of the second medicament 2 may be set after a second minimum dose of the first medicament 1 is set. In an example, the collar 208 and fixed dose setting mechanism 204 may be configured to (i) set a half fixed dose of the second medicament 2 upon setting of a first minimum variable dose of the first medicament 1 and (ii) set a full fixed dose of the second medicament 2 upon setting of a second threshold dose of the first medicament 1. Such a profile is advantageous for certain therapies where it is beneficial for the dose of the second medicament 2 to increase in fixed stepped increments as the corresponding dose of the first medicament 1 increases. Each of these stepped increases only occurs once a specific predefined threshold dose of the first medicament 1 has been exceeded.
Various examples of such a stepped, fixed dose profile are shown in
An example advantage of a drug delivery device such as drug delivery device 200 is the ability to define where the half and full set points (or any desired percentage) of the second medicament 2 occur relative to the setting of the first medicament 1. Potentially several variations of the drug delivery device could be manufactured and user prescribed to fit a variety of specific user needs. For example, a user who may typically use a high amount of the first medicament 1 may wish to split their dose (e.g., set and inject half a dose in one location and then set and inject the second half dose in another location) or may be required to split their dose to avoid injecting a high volume of medicament in a single location (which can, for example, cause discomfort). Such a user may benefit from the second threshold of the first medicament 1 (which determines when the full dose of the second medicament is set) being at a much higher point than their half dose of the first medicament, for example, in order to reduce the risk of overdosing the secondary medicament during split dose scenarios. An example of such a dose profile is shown in
In another example, a user who may typically use a small amount of the first medicament 1 may ideally obtain their full dose of the second medicament 2 at their relatively low dose of the first medicament 1. The user may thus avoid the need for injecting more of the first medicament 1 than desired to obtain a full fixed dose of the second medicament 2. An example of such a dose profile is shown in
The setting and dispensing phases of drug delivery device 200 are depicted in detail in
As shown in
After a given amount of rotation, the pin 209 enters the third/flat section 244, as shown in
After the full fixed dose of the second medicament is set, the dose setter 206 may be rotated further to set a higher dose of the first medicament 1. In particular, when the pin 209 travels through the third, flat section 244, the pin then enters the fourth/helical section 246. In this section, the helical section 246 is the same pitch as the dial sleeve of the variable dose setting mechanism and so results in the collar 208 rotating past the pin and not loading the fixed dose setting mechanism. The pin may then exit the fourth, helical section 246 and the user can continue to set a higher dose of the first medicament, if desired.
In another example, the collar 208 may not include a fourth helical section. Rather, the collar may simply end at the third, flat section 244, and when the pin 209 exits this flat section, the dose setter could continue to be rotated to set a higher dose of the first medicament, if desired.
After setting the desired dose of the first medicament, the user may dispense the medicament.
Further rotation forces the pin 210 to move through the helical section 242. Since the pitch matches that of the dial sleeve 212, the helical section winds back past the pin 209, and this action does not cause axial movement of the fixed dose setting mechanism in distal direction 236. However, the pin 209 then enters the flat section 240, as shown in
Beneficially, the groove sections can be modified in order to achieve a desired dose profile. For example, the groove may have more flat sections and more helical sections, and thus may result in more steps in the stepped, fixed dose profile. For instance, the groove sections could be designed such that the drug delivery device is capable of setting a ¼ dose, ½ dose, ¾ dose, and a full dose.
As another example, rather than having a flat section, the collar 208 may comprise a groove having (i) a first section that is a first helical section having a first pitch and (ii) a second section that is a second helical section having a second pitch different from the first pitch.
In yet another example, a drug delivery device having a collar may be configured to deliver medicament according to a dose profile that involves delivering a fixed ratio, a first fixed dose, an offset fixed ratio, and a second fixed dose. Similar to the example discussed above with respect to
An example of a dose profile that involves a fixed ratio, a first fixed dose, an offset fixed ratio, and a second fixed dose is shown in
A pulsed dose profile achieved by drug delivery device 300 could comprise a pulsed dose profile of a second medicament 2 contained within a second reservoir or cartridge 6. For instance, in such a device 300, a first fixed dose amount of the second medicament 2 may be set after a first minimum dose or first threshold dose of the first medicament 1 is set. Similarly, a second fixed dose or a second amount of the second medicament 2 (i.e., the second fixed dose being greater than the first fixed dose) may be set after a second minimum dose or second threshold dose of the first medicament 1 is set. In an example, the collar 308 and fixed dose setting mechanism 304 may be configured to (i) set a first fixed dose (or proportion of a dose) of the second medicament 2 upon setting of a first minimum variable dose of the first medicament 1, (ii) set a second fixed dose (or proportion of a dose) of the second medicament 2 upon setting of a second threshold dose of the first medicament 1, (iii) administer the set fixed dose of the second medicament 2 using a plurality of discrete pulses. The first fixed dose could comprise a certain percentage of a target fixed dose and the second fixed dose could comprise the balance of the target fixed dose. As just one example, assume that the target fixed dose comprises 100 Units of the second medicament. With such a target dose, the first fixed dose could comprise 40% of a target fixed dose (i.e., 40 Units) and the second fixed dose could comprise 60% or the remaining balance (i.e., 60 Units) of the target fixed dose (i.e., 100 Units). As those of skill in the art will recognize, alternative fixed dose and target dose arrangements may also be used.
Such a profile can be advantageous for certain therapies where it is beneficial for the dose of the second medicament 2 to increase in fixed stepped increments as the corresponding dose of the first medicament 1 increases. In one preferred arrangement, a stepped increase occurs after a specific predefined threshold dose of the first medicament 1 has been exceeded. Moreover, depending on the configuration of the variable dose setting mechanism 302 and the fixed dose setting mechanism 304 (i.e., particularly the collar 308 and the fixed dose piston rod 316), the pulsed nature of administration can be modified.
One example of such a stepped, fixed dose profile that can be achieved by the drug delivery device 300 is the profile 450 illustrated in
If the combined first and second medicament dose would be administered at this point in the profile 450 designated as “Ratchet point 1,” a dose comprising 50% of the target fixed dose 459 of the second medicament 2 would be administered by way of three pulses: Pulse C 504, Pulse B 502, and Pulse A 500. This point has been designated as “Ratchet point 1” in profile 450 since this defines the minimum required dose that needs to be set for the first medicament 1 in order for the movable rack of the fixed dose setting mechanism 304 to move proximally to reach the first ratchet element set provided on the piston rod. The set dose 454 of the first medicament 1, a 30 Unit dose of the first medicament 1, would be administered continuously during this dose administration step.
The profile 450 further comprises a second step 456. The second step 456 occurs when a second threshold dose 458 (e.g., 60 Units in the embodiment provided) of the first medicament 1 is set. The second step 456 results in a second part or the remaining portion of the target dose 459 of the second medicament 2 being set. In this example, the target dose 459 is a full dose (e.g., maximum or target dose) of the second medicament 2. However, it should be understood that the dose 459 could be any desired percentage of the second medicament 2. This point has been designated as “Ratchet point 2” in profile 450 since this point defines a second minimum dose that is required that needs to be set for the first medicament 1 in order for the movable rack of the fixed dose setting mechanism 304 to move proximally and thereby reach a second ratchet element set provided along the outer surface of the fixed dose piston rod.
Once a user sets a 60 Unit dose of the first medicament, the combined dose would comprise the targeted dose 459 comprising 100% of the second medicament and 60 Units of the first medicament 1. Administering this target fixed dose 459 would be administered by way of six sequential pulses: Pulse F 510, Pulse E 508, Pulse D 506, Pulse C 504, Pulse B 502, and Pulse A 500. The set dose 458 of the first medicament 1, a 60 Unit dose of the first medicament 1, would be administered continuously during the entire dose administration process. To administer six pulses of the second medicament during dose administration, a groove 322 of the collar 308 would comprise at least six threaded sections.
In this example, after the full dose 459 is set, the user may continue to set a higher dose of the first medicament 1. In addition, although only two steps 452, 456 are shown in this example dose profile 450, more steps are possible.
An example advantage of Applicants' drug delivery device, such as the drug delivery device 300 illustrated in
Potentially several variations of the drug delivery device 300 could be manufactured and user prescribed to fit a variety of specific user needs. For example, a user who may typically use a high amount of the first medicament 1 may wish to split their dose (e.g., set and inject half a dose in one location and then set and inject the second half dose in another location) or may be required to split their dose to avoid injecting a high volume of medicament in a single location (which can, for example, cause discomfort). Such a user may benefit from the second threshold of the first medicament 1 (which determines when the full dose of the second medicament is set) being at a much higher point than their half dose of the first medicament, for example, in order to reduce the risk of overdosing the secondary medicament during split dose scenarios.
Referring now to
However, as compared to the device 200 illustrated in
The modified fixed dose setting mechanism 304 comprises a modified moving rack 314 along with a fixed dose piston rod arrangement 316. In this arrangement, and as illustrated in
At its distal end 315b, the moving rack 314 comprises a set of one way ratchet arms 312a,b. In addition, the modified fixed dose setting mechanism 304 further comprises a fixed dose piston rod 316. This fixed dose piston rod 316 comprises a plurality of ratchet element sets 370a,b; 372a,b; 374a,b; 376a,b; 378a,b; 380a,b; 382a,b; 384a,b; and 386a,b situated along an outer surface 342 of the rod 316. As illustrated, these ratchet elements sets 370a,b-386a,b are positioned at predetermined positions along the outer surface 342 of the piston rod 316. As will be explained in greater detail below, as the fixed dose setting mechanism 304 and hence the moving rack 314 is moved in a proximal direction 330 a certain predefined distance during certain dose setting steps, the one way ratchet arms 312a,b of the movable rack 314 will pulled in the proximal direction 330. If the one way ratchet arms 312a,b are moved in the proximal direction 330a sufficient distance, these ratchet arms 312a,b will eventually ride over a ratchet element set so as to set a predetermined, fixed dose.
As can be seen from
It is this ratchet element set spacing and its relation to the amount of axial movement of the pin 310 and pin sleeve 307 of collar 308 during each flat thread section on the collar during dialing and dispense that determines a number of important drug delivery device design parameters. For example, the distance D1360 between the first ratchet element set 370a,b and the distal end 318 of the fixed dose piston rod 316 defines the first predetermined fixed dose. Similarly, the distance D2 between the first ratchet element set 370a,b and the second ratchet element set 372a,b determines (in conjunction with D1) the minimum dose of the first medicament that needs to be dialed before the second predetermined fixed dose of the secondary medicament is set. In addition, the distances D1 and D2 along with the configuration of groove 322 determine the number of discrete pulses of the secondary medicament 2 that can be delivered during a dispense action (i.e., after one or more of the ratchet element sets have been overcome by the one way ratchet arms 312a,b).
In this case, the fixed dose piston rod 316 comprises nine ratchet element sets; however, this number of ratchet element sets can vary as needed. For example, having ratchet element sets in multiples of 7 may be potentially beneficial as it relates directly to the days in a week, making planning for replacement prescriptions easier for a target user having a once a day dosing regime. As those of skill will recognize, alternative ratchet element set configurations are possible.
The various ratchet element sets 370a,b-386a,b define a plurality of target doses that may be administered by way of the fixed dosing mechanism 304. Used in combination with the groove 322 provided on the modified collar arrangement 308, these ratchet sets 370a,b-386a,b work in cooperation with the one way ratchet arms 312a,b so as to allow for administering a fixed dose by way of a plurality of incremental pulses. In other words, the fixed dose setting mechanism 304 allows for the non user-settable fixed dose to increase in increments based on the value of the dialed variable dose of the first medicament 1 and also allows this settable fixed dose to be administered by way of a plurality of discrete pulses.
Returning to
Similar to the drug delivery device 200 illustrated in
Similar to collar 208, the collar 308 comprises a groove 322 that has a plurality of flat sections 340a-d and a plurality of helical sections 350a-d. (e.g., see
The setting and dispensing phases of drug delivery device 300 are depicted in detail in
As shown in
As shown in
Further rotation of the dose setter 306 then forces the pin 309 to travel from the second helical section 350b through to the second flat section 340b of the groove 322. This additional dose setting step is illustrated in
As shown in
As illustrated in
After the first predetermined fixed dose of the second medicament 2 has been set, the dose setter 306 may be rotated further to set a higher dose of the first medicament 1. For example, further rotation of the dose setter 306 then forces the pin 309 to travel through yet another helical section 350d and then a subsequent fourth flat section 340d. With reference to
After setting the desired dose of the first medicament 1, the user may dispense the medicament. As will be explained with reference to
To begin to administer this set dose, referring to
Further movement in the rotational direction 334 and thus distal direction 336 causes the collar 308 to push against the pin 309 and moves the pin 309 through the fourth flat section 340d and into the fourth helical section 350d. This action continues to dispense the first medicament 1 but not of the second medicament 2. As such, the piston rod 316 does not move in the distal direction and no administration of the second medicament 2 occurs during this step where the pin 309 resides in the fourth helical section 350d. This first dosing step of administering only the primary medicament as the pin moves from the fourth thread section 350d and through the fourth helical section 340d is illustrated as the complete dosing step 502 in the profile 500 illustrated in
Continued pressure on the dose button 332 causes further rotation of the collar 308 during dose dispense. This forces the pin 309 to move out of the fourth helical section 340d and into the third flat thread section 350d to initiate the first pulsed dose of the first medicament. For example,
Further rotation of the dose setter 306 during dispense causes the pin 309 to exit the second flat section 340b and enter the second helical section 350b of the groove 322. This is illustrated in
When the dose setter 306 is fully depressed back to its starting position (i.e., pre-set position as illustrated in
Beneficially, the various flat sections 340a-d and helical sections 350a-d of the groove 322 can be modified in order to achieve a desired dose profile. For example, the groove 322 may have more flat sections and more helical sections, and thus may result in more steps in the pulsed, fixed dose profile. Additionally, the angular arc of the flat sections can be varied to change the relative duration of the individual pulses, as required.
One advantage of a drug delivery device having a collar such as collar 308 relates to the fact that the delayed setting of the second medicament means that a user may perform a priming step with only the first medicament (and not the second medicament). This priming can be carried out as many times as necessary (each with a volume up to the minimum threshold of the first medicament) without dispensing any of the second medicament. For a multi-dose drug delivery device, a profile of this type may, for example, be beneficial where (i) the second medicament dose not require repeated priming, (ii) the simultaneous priming of the first and second medicament might mask an unsuccessful priming of the first medicament, or (iii) the second medicament is a particularly expensive compound that preferably is not wasted. Other examples are possible as well.
As described above, prior to each dose, the user could potentially vary the threshold at which the full dose of the second medicament is set, or the user may leave the threshold unchanged from its previously set value. Similarly, the half dose threshold could also potentially be varied by a user or by a prescribing healthcare professional prior to handover of the device.
As mentioned above, in some examples of the drug delivery devices described above, the device could be configured to have the fixed dose increase in a plurality of steps, such as two or more steps, each of which is set when an associated defined threshold of the first medicament is set.
The disclosed drug delivery devices may be suited towards a modular disposable or re-usable platform in terms of managing drug wastage. This is because there is a risk of one medicament being finished before the other unless there is a strict 1:1 ratio between the two medicaments. However, where each side is resettable, new medicament reservoirs can be inserted and the device can continue to be used. Possible embodiments for a modular disposable platform could involve, but are not limited to, the replacement of the entire device mechanism fitted with a new primary pack. Suitable re-engagement features may be integrated into the device platform to facilitate the alignment and fastening of the individual device mechanisms together in a robust and user friendly fashion. It is possible that such features could be arranged to define the permissible functionality of the two individual elements on their own.
A possible re-usable platform would feature spindles that could be back wound into their respective devices once they had reached the limits of travel, such as those known in the art. In addition to this functionality, the platform would feature a means of replacing the medicament reservoir or reservoirs after the resetting of one or both spindles.
Exemplary embodiments of the present invention have been described. Those skilled in the art will understand, however, that changes and modifications may be made to these embodiments without departing from the true scope and spirit of the present invention, which is defined by the claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10192846 | Nov 2010 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2011/071143 | 11/28/2011 | WO | 00 | 5/16/2013 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2012/072565 | 6/7/2012 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5253785 | Haber et al. | Oct 1993 | A |
| 5505704 | Pawelka et al. | Apr 1996 | A |
| 5582598 | Chanoch | Dec 1996 | A |
| 5584815 | Pawelka et al. | Dec 1996 | A |
| 20040011816 | Muhlgauer et al. | Jan 2004 | A1 |
| 20100094205 | Boyd et al. | Apr 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 19930631 | Jan 2001 | DE |
| 852572 | Oct 1960 | GB |
| H08-103495 | Apr 1996 | JP |
| H08-503385 | Apr 1996 | JP |
| H08-503874 | Apr 1996 | JP |
| 2826196 | Nov 1998 | JP |
| 2000-262525 | Sep 2000 | JP |
| 9403392 | Feb 1994 | WO |
| 9422507 | Oct 1994 | WO |
| 2010053569 | May 2010 | WO |
| Entry |
|---|
| International Preliminary Report on Patentability for Int. App. No. PCT/EP2011/071143, mailed Jun. 13, 2013. |
| International Search Report and Written Opinion for Int. App. No. PCT/EP2011/071143, completed Jan. 5, 2012. |
| Japanese Office Action for JP App. No. 2013-540406 dated Oct. 6, 2015. |
| Number | Date | Country | |
|---|---|---|---|
| 20130245566 A1 | Sep 2013 | US |
